Sabbah A, Bonneau J C, Le Dauphin C, Heulin M G
Laboratoire d'Immuno-Allergologie, CHRU, Angers.
Allerg Immunol (Paris). 1988 Dec;22 Suppl 10:40-8.
21 infected asthmatics were involved in this study, divided into three groups: Group 1 (G1): 7 subjects who received Ribomunyl. Group 2 (G2): 7 subjects who received anti-influenza vaccine, replaced on the 8th day by Ribomunyl. Group 3 (G3): 7 subjects who received the anti-influenza vaccine. Every patient had a IMC assessment on days 0, 8 and 30 that was composed of: 1. An RE test to show the Ly T11 receptors. 2. A study of the lymphocyte sub-populations CD3, CD4 and CD8, that respectively exhibit the LyT, T-helper and T-suppressor receptors. 3. Lymphocyte function was studied by stimulation of the lymphocytes by lectins, PHA (Ly T), Con A (Ly Ts) PKWM (Ly 8): by TB co-operation). 4. Measurement of total IgE. Only the lymphocyte stimulation tests by lectins showed a significantly raised response in the subjects of G1, who received Ribomunyl. IAV and Ribomunyl (G2) or IAV alone (G3) showed lymphocytes responses that were statistically less than G1. It seemed as though the IAV retarded the Ribomunyl response in IMC. The RE test and the study of the sub-populations did not show any significant differences between the groups. No differences between the total IgE levels could be seen in the groups. This study indicates the possibilities in the treatment of super-infected asthmatics with Ribomunyl alone, since the anti-influenza vaccine had a tendency to retard cell-mediated immunity.
21名感染的哮喘患者参与了本研究，分为三组：第1组（G1）：7名接受力保美达的受试者。第2组（G2）：7名接受抗流感疫苗的受试者，在第8天换用力保美达。第3组（G3）：7名接受抗流感疫苗的受试者。每位患者在第0天、第8天和第30天进行免疫细胞化学（IMC）评估，评估内容包括：1. 一项用于显示Ly T11受体的RE试验。2. 对淋巴细胞亚群CD3、CD4和CD8的研究，它们分别表现出LyT、辅助性T细胞和抑制性T细胞受体。3. 通过凝集素、PHA（Ly T）、刀豆蛋白A（Ly Ts）、PKWM（Ly 8）刺激淋巴细胞来研究淋巴细胞功能（通过结核菌协同作用）。4. 总IgE的测量。只有接受力保美达的G1组受试者经凝集素刺激的淋巴细胞试验显示出显著升高的反应。单独使用流感病毒疫苗（IAV）和力保美达（G2）或单独使用IAV（G3）的淋巴细胞反应在统计学上低于G1组。似乎IAV延缓了IMC中力保美达的反应。RE试验和亚群研究在各组之间未显示出任何显著差异。各组之间总IgE水平未见差异。本研究表明了单独用力保美达治疗合并感染的哮喘患者的可能性，因为抗流感疫苗有延缓细胞介导免疫的趋势。
